

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED**

**通用環球醫療集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code : 2666)**

### **UNAUDITED OPERATION SUMMARY OF THE GROUP FOR THE THIRD QUARTER OF 2023**

This announcement sets out the unaudited operation summary of Genertec Universal Medical Group Company Limited (the “**Company**”), together with its subsidiaries (the “**Group**”), for the third quarter ended 30 September 2023.

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

During the third quarter of 2023, the Group promoted business development of all sectors. For the nine months ended 30 September 2023, the Group achieved a stable growth in operating results: the revenue of the Group increased by approximately 15.0% as compared with the corresponding period of 2022, the profit for the period increased by approximately 5.7% as compared with the corresponding period of 2022, among which the profit of the finance business remained stable as compared with the corresponding period of 2022, and the profit of the healthcare business increased by approximately 60% as compared with the corresponding period of 2022, and the profit for the period attributable to ordinary shareholders of the parent increased by approximately 4.3% as compared with the corresponding period of 2022, among which:

In respect of integrated healthcare business, focusing on the primary goals of “comfortable environment, top-notch services, advanced technology and efficient operation”, the Group continued to empower the development of the hospitals run by state-owned enterprises and constantly improve operation efficiency and effectiveness. The member medical institutions managed by the Group performed well in the first three quarters of 2023: total number of outpatient and emergency visits increased by approximately 16.5% as compared with the corresponding period of 2022; visits for medical examination increased by approximately 13.3% as compared with the corresponding period

of 2022; the number of inpatients increased by approximately 19.3% as compared with the corresponding period of 2022; total medical business income grew by approximately 9.0% as compared with the corresponding period of 2022.

In respect of specialties and healthcare industry, with the business foundation and professional core talent team of our own hospital group, the Group strived to build replicable capabilities of specialties and industry operation, so as to create new profit growth drivers for the company. The work of specialties and healthy industry operation is conducted as scheduled, and the self-expansion business and external mergers and acquisitions are also progressing smoothly. During the third quarter of 2023, for specialties, the Group have completed the acquisition of Beth Hesda Nephrology Hospital (畢士大(成都)腎病專科醫院) and Haiyang Senzhikang Hospital Co., Ltd. (海陽森之康醫院), and continued to facilitate the acquisition programme of other specialist hospitals and hemodialysis centres; for the life circle management of equipment, the Group acquired 85% equity interests of Casstar Medical Technology Wuxi Co., Ltd. (凱思軒達醫療科技無錫有限公司) at the consideration of RMB467.5 million, which has completed its closing and was incorporated into the consolidated financial statements of the Group this October.

In respect of finance business, the Group always took risk control as a top priority, promoted the investment of interest-generating assets in an orderly manner, and were committed to ensuring quality project development for our customers. Regarding the cost, by keeping abreast of the market development, we strived to control the scale of overseas financing moderately, manage exchange rate risk prudently and neutrally, and arrange financing structure properly, so as to ensure liquidity sufficiency and reasonableness and stability of debt structure while minimising the pressure of rising costs as a result of US Dollar interest rate hikes on the offshore markets through actively usage of various financing instruments at home and abroad. As at 30 September 2023, interest-earning assets continued to increase as compared with the middle of 2023, net interest margin and net interest spread both decreased slightly, asset quality still remained at a good level, and the provision coverage remained prudent.

In addition, references are made to the Company's announcements dated 20 December 2021, 30 May 2022, 6 July 2022, 5 September 2022, 13 January 2023, 4 April 2023, and 29 August 2023 in relation to the issuance of the medium-term notes with an aggregate principal amount of RMB3.50 billion in the inter-bank market in the People's Republic of China (the "PRC") by China Universal Leasing Co., Ltd. (中國環球租賃有限公司) ("**Universal Leasing**"), a wholly-owned subsidiary of the Company. In accordance with the relevant laws and regulations of the PRC, the unaudited consolidated financial information of Universal Leasing for the nine months ended 30 September 2023 (the "**Universal Leasing Consolidated Financial Information**") has been published on the websites of Shanghai Clearing House (www.shclearing.com) and China Foreign Exchange Trade System (www.chinamoney.com.cn) on 30 October 2023. The Company's board of directors would like to draw the attention of its shareholders and investors to the following principal financial data of Universal Leasing:

## **PRINCIPAL CONSOLIDATED FINANCIAL DATA OF UNIVERSAL LEASING**

*Unit: Thousand Yuan  
Currency: RMB*

**As at 30 September 2023  
(unaudited)**

**As at 31 December 2022  
(audited)**

Total assets	85,101,624	76,507,178
Total equity	22,218,472	20,476,986
	<b>For the nine months ended 30 September 2023 (unaudited)</b>	<b>For the nine months ended 30 September 2022 (unaudited)</b>
Operating income	9,877,084	8,586,687
Profit for the period	1,782,573	1,727,114
Net cash flows from / (used in) operating activities	(3,329,062)	2,555,008

The Company hereby reminds investors that the above unaudited operation summary for the third quarter ended 30 September 2023 was prepared based on the Group's internal figures and management accounts which have not been reviewed or audited by the auditors of the Group. The Universal Leasing Consolidated Financial Information was prepared in accordance with the General Accepted Accounting Principles of the PRC, which may require adjustment during the course of auditing of the financial results of the Group, and the information contained therein is limited solely to the operation of Universal Leasing, which does not provide a full picture of the operation status of the Group or comparison with the Group.

**Investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Genertec Universal Medical Group Company  
Limited**  
通用環球醫療集團有限公司  
**Peng Jiahong**  
*Chairwoman of the Board*

Beijing, PRC, 30 October 2023

*As at the date of this announcement, the executive directors of the Company are Ms. Peng Jiahong (Chairwoman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive directors of the Company are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas*